comparemela.com

Latest Breaking News On - Yannick tetzlaff - Page 9 : comparemela.com

INVENTIVA: 2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States

INVENTIVA: 2020 Full-Year Results: Major advances in NASH and significantly extended cash runway through successful IPO in the United States
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen

University, “ The need to develop reliable NASH biomarkers is both clear and urgent as the utility of liver biopsy, the only diagnostic approach currently available, is limited due to its invasive nature, poor patient acceptability and sampling variability. So we are very much looking forward to working with Inventiva on lanifibranor, a drug candidate that has shown very promising results in the field of NASH. Given the efficacy shown by lanifibranor during the NATIVE Phase IIb trial and the promising biomarker dataset available, we are confident that we will be able to meet our objective to develop one or several robust biomarkers or composite biomarker score

INVENTIVA: Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen

INVENTIVA: Inventiva announces collaboration on non-invasive biomarkers to identify patients responding to lanifibranor with regards to NASH resolution and fibrosis improvemen
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

INVENTIVA: Inventiva to participate at several investor conferences in March 2021

INVENTIVA: Inventiva to participate at several investor conferences in March 2021 Daix (France), February 24, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, will participate at three upcoming investor conferences in March 2021. The event details are as follows: Conference n°1: Credit Suisse Virtual 2021 London Global Healthcare Conference Event type: One-on-one investor meetings Date: Tuesday-Thursday, March 2-4, 2021 Format: Virtual event Event type: Corporate presentation, fireside chat, one-on-one investor meetings

Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva to participate at several investor conferences in March 2021

Investegate |INVENTIVA Announcements | INVENTIVA: Inventiva to participate at several investor conferences in March 2021
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.